Dr Reddy’s Laboratories (RDY) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Dr. Reddy’s Laboratories has been named as a defendant in multiple lawsuits related to the Revlimid antitrust action in the United States. The company, along with other defendants, has filed motions to dismiss these lawsuits and plans to vigorously defend its position. The outcome of these legal challenges could impact Dr. Reddy’s stock performance and market perception.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
